“Non-Trippy” Magic Mushrooms: New Compounds Offer Therapeutic Potential Without Hallucinations

Scientists are making strides in harnessing the therapeutic potential of psilocybin, the psychoactive compound in “magic mushrooms,” while minimizing the unwanted hallucinogenic effects. Recent research published in ACS’ Journal of Medicinal Chemistry details the creation of modified psilocin molecules that maintain biological activity but produce fewer psychedelic-like responses.

The Promise of Psilocybin and the Challenge of Hallucinations

Psilocybin is gaining attention for its potential to treat neuropsychiatric conditions, including depression, anxiety, substance leverage disorders, and certain neurodegenerative diseases. However, the intense hallucinogenic effects associated with the compound have presented a barrier to wider medical use.

Engineering Modified Psilocin Derivatives

Researchers led by Sara De Martin, Andrea Mattarei, and Paolo Manfredi synthesized five chemical variants of psilocin, the active form of psilocybin when processed in the body. These compounds were designed to release the active molecule into the brain more slowly and steadily, aiming to reduce hallucinogenic effects while preserving therapeutic benefits. The goal was to dissociate the therapeutic effects from the psychedelic experience.

Promising Results in Preclinical Studies

Initial laboratory tests using human plasma identified compound “4e” as the most promising candidate. 4e demonstrated strong stability during absorption and a gradual release of psilocin. Further testing in mice compared 4e to pharmaceutical-grade psilocybin. Researchers found that 4e efficiently crossed the blood-brain barrier, maintaining a lower but more sustained presence in the brain compared to psilocybin.

Notably, mice treated with 4e exhibited significantly fewer “head twitches”—a standard indicator of psychedelic activity in rodents—than those treated with psilocybin. This occurred despite 4e strongly interacting with serotonin receptors, suggesting the difference lies in the rate and amount of psilocin released into the brain. The slower release appears to be key.

Future Directions and Potential Applications

These findings suggest that it may be possible to develop stable, psilocin-based compounds that activate serotonin receptors in the brain while minimizing the mind-altering effects commonly associated with psychedelics. Researchers believe this could broaden the therapeutic applications of psilocybin to include conditions like Alzheimer’s disease, in addition to mood and anxiety disorders.

Further research is needed to fully understand the mechanisms of these new molecules and to evaluate their safety and therapeutic potential in humans. The authors of the study have acknowledged funding from MGGM Therapeutics, LLC, and NeuroArbor Therapeutics Inc., and some are inventors on related patents.

Key Takeaways

• Scientists have engineered modified versions of psilocin that reduce hallucinogenic effects.
• Compound 4e showed the most promise in preclinical studies, demonstrating stable absorption and a gradual release of psilocin.
• Mice treated with 4e exhibited fewer psychedelic-like behaviors while maintaining serotonin receptor activity.
• This research opens the door to developing psychedelic-inspired medicines with a reduced risk of unwanted side effects.